Jonathan Wolleben
Stock Analyst at Citizens
(4.55)
# 253
Out of 5,156 analysts
240
Total ratings
51.9%
Success rate
27.11%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Maintains: Market Outperform | $105 → $96 | $38.22 | +151.18% | 19 | Mar 2, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Market Outperform | $167 → $176 | $93.00 | +89.25% | 7 | Feb 27, 2026 | |
| GPCR Structure Therapeutics | Maintains: Market Outperform | $120 → $113 | $56.50 | +100.00% | 12 | Feb 27, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Market Outperform | $102 → $112 | $96.66 | +15.87% | 14 | Feb 26, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Market Outperform | $140 → $132 | $88.78 | +48.68% | 14 | Feb 26, 2026 | |
| SION Sionna Therapeutics | Initiates: Market Outperform | $63 | $37.53 | +67.87% | 1 | Feb 24, 2026 | |
| QNCX Quince Therapeutics | Downgrades: Market Perform | n/a | $0.11 | - | 3 | Jan 30, 2026 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Market Outperform | $527 → $745 | $433.20 | +71.98% | 15 | Jan 20, 2026 | |
| DBVT DBV Technologies | Maintains: Market Outperform | $21 → $45 | $22.90 | +96.51% | 16 | Dec 17, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Market Outperform | $33 → $35 | $5.38 | +550.56% | 9 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $11 → $10 | $5.43 | +84.16% | 10 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $254 → $259 | $62.11 | +317.00% | 9 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $29 → $28 | $17.30 | +61.85% | 6 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $15 → $14 | $3.88 | +260.82% | 14 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $27 → $25 | $8.62 | +190.02% | 10 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $20 | $10.00 | +100.00% | 1 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $20 → $29 | $9.94 | +191.75% | 18 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $5.69 | +216.34% | 13 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $52 | $26.51 | +96.15% | 12 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $1.89 | +323.28% | 8 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $0.72 | +1,971.82% | 3 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $5.67 | +235.10% | 9 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $38 | $27.94 | +36.01% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $50 | $43.22 | +15.69% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $48.42 | +85.87% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $134.03 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $544.88 | -10.99% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $64 | $10.77 | +494.52% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $27.51 | -12.76% | 1 | May 12, 2023 |
Crinetics Pharmaceuticals
Mar 2, 2026
Maintains: Market Outperform
Price Target: $105 → $96
Current: $38.22
Upside: +151.18%
Rhythm Pharmaceuticals
Feb 27, 2026
Maintains: Market Outperform
Price Target: $167 → $176
Current: $93.00
Upside: +89.25%
Structure Therapeutics
Feb 27, 2026
Maintains: Market Outperform
Price Target: $120 → $113
Current: $56.50
Upside: +100.00%
Protagonist Therapeutics
Feb 26, 2026
Maintains: Market Outperform
Price Target: $102 → $112
Current: $96.66
Upside: +15.87%
Mirum Pharmaceuticals
Feb 26, 2026
Maintains: Market Outperform
Price Target: $140 → $132
Current: $88.78
Upside: +48.68%
Sionna Therapeutics
Feb 24, 2026
Initiates: Market Outperform
Price Target: $63
Current: $37.53
Upside: +67.87%
Quince Therapeutics
Jan 30, 2026
Downgrades: Market Perform
Price Target: n/a
Current: $0.11
Upside: -
Madrigal Pharmaceuticals
Jan 20, 2026
Maintains: Market Outperform
Price Target: $527 → $745
Current: $433.20
Upside: +71.98%
DBV Technologies
Dec 17, 2025
Maintains: Market Outperform
Price Target: $21 → $45
Current: $22.90
Upside: +96.51%
Sagimet Biosciences
Nov 14, 2025
Maintains: Market Outperform
Price Target: $33 → $35
Current: $5.38
Upside: +550.56%
Nov 13, 2025
Maintains: Market Outperform
Price Target: $11 → $10
Current: $5.43
Upside: +84.16%
Nov 11, 2025
Maintains: Market Outperform
Price Target: $254 → $259
Current: $62.11
Upside: +317.00%
Nov 11, 2025
Maintains: Market Outperform
Price Target: $29 → $28
Current: $17.30
Upside: +61.85%
Nov 7, 2025
Maintains: Market Outperform
Price Target: $15 → $14
Current: $3.88
Upside: +260.82%
Nov 5, 2025
Maintains: Market Outperform
Price Target: $27 → $25
Current: $8.62
Upside: +190.02%
Nov 3, 2025
Initiates: Market Outperform
Price Target: $20
Current: $10.00
Upside: +100.00%
Oct 1, 2025
Maintains: Market Outperform
Price Target: $20 → $29
Current: $9.94
Upside: +191.75%
Aug 19, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $5.69
Upside: +216.34%
Aug 13, 2025
Maintains: Market Outperform
Price Target: $55 → $52
Current: $26.51
Upside: +96.15%
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $8
Current: $1.89
Upside: +323.28%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $0.72
Upside: +1,971.82%
May 23, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $5.67
Upside: +235.10%
Apr 10, 2025
Initiates: Market Outperform
Price Target: $38
Current: $27.94
Upside: +36.01%
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $43.22
Upside: +15.69%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $48.42
Upside: +85.87%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $134.03
Upside: -
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $544.88
Upside: -10.99%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $64
Current: $10.77
Upside: +494.52%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $27.51
Upside: -12.76%